Non-Hemostatic Roles of von Willebrand Factor in Gastrointestinal Angiodysplasia: Mechanisms and Therapeutic Implications
Alan (mail bueno) Nurden shared a post on LinkedIn:
“This is an up-to-date and well-written review highlighting the non-hemostatic role of von Willebrand factor in angiodysplasia of the gastro-intestinal tract; a rare condition that complicates life for patients with von Willebrand disease. The role of VWF multimers in binding angiopoietin-2 and growth factors such as vascular endothelial growth factor and presenting them to endothelial cells via avβ3 is emphasized. The authors discuss the signaling pathways that cause increased angiogenesis in vascular deformation syndromes and how these represent possible novel therapeutic targets. The authors are to be congratulated for an informative and highly readable review. It will be interesting to see how this relates to gastrointestinal bleeding in patients with Glanzmann thrombasthenia where angiodysplasia linked to gastrointestinal bleeding is also seen, often for elderly patients, greatly interfering with their quality of life.”
Read the full paper here.
Title: von Willebrand disease and angiodysplasia: a wider view of pathogenesis in pursuit of therapy
Authors: Christina Crossette-Thambiah, Anna M. Randi, Michael Laffan

Find similar posts on Hemostasis Today.
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke
-
Feb 26, 2026, 15:15Shannon Farmer: What Happens to Vital Signs Pre and Post 1-Unit and 2-Unit RBC Transfusion?
-
Feb 26, 2026, 15:08Emmanuel J Favaloro: When Is A ‘Subtype’ of VWD Not Really VWD?
-
Feb 26, 2026, 15:03Gregory Piazza: Importance of Recognizing PE As A Wide Spectrum of Presentations and Greater Range of Adverse Outcomes
-
Feb 26, 2026, 14:57Abdulla A. Damluji: Sex As An Effect Measure Modifier Between Frailty and Outcomes in AMI Patients
-
Feb 26, 2026, 14:48Ney Carter Borges: The APERITIF Trial Clarifies Rivaroxaban’s Role in LVT
-
Feb 26, 2026, 14:44Wolfgang Miesbach: Synovitis and Haemophilia in Focus at GTH2026
-
Feb 26, 2026, 14:40Al-Ola Abdallah: How Much Does It Cost to Publish in Hematology and Oncology Journals